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The MYC oncogene encodes MYC, a transcription
factor that binds the genome through sites termed
E-boxes (50-CACGTG-30), which are identical to the
binding sites of the heterodimeric CLOCK-BMAL1
master circadian transcription factor. Hence, we hy-
pothesized that ectopic MYC expression perturbs
the clock by deregulating E-box-driven compo-
nents of the circadian network in cancer cells.
We report here that deregulated expression of
MYC or N-MYC disrupts the molecular clock
in vitro by directly inducing REV-ERBa to dampen
expression and oscillation of BMAL1, and this could
be rescued by knockdown of REV-ERB. REV-ERBa
expression predicts poor clinical outcome for N-
MYC-driven human neuroblastomas that have
diminished BMAL1 expression, and re-expression
of ectopic BMAL1 in neuroblastoma cell lines sup-
presses their clonogenicity. Further, ectopic MYC
profoundly alters oscillation of glucose metabolism
and perturbs glutaminolysis. Our results demon-
strate an unsuspected link between oncogenic
transformation and circadian and metabolic dys-
rhythmia, which we surmise to be advantageous
for cancer.Cell MetabINTRODUCTION
The molecular clock regulates rhythmic gene expression and
synchronizes cellular metabolism with food availability and the
24-hr sleep-wake cycle (Asher and Schibler, 2011; Bass and
Takahashi, 2010; Sahar and Sassone-Corsi, 2012). Cancer cells
are known for having a growth advantage from deregulated
metabolism, such as through MYC-driven aerobic glycolysis or
glutaminolysis that supports biosynthesis and cell growth, but
it is unknown how or whether the MYC oncogenic transcription
factor could disrupt and uncouplemetabolism from the influence
of the molecular clock (Cantor and Sabatini, 2012).
Oncogenic expression of the MYC family of transcription
factors lies at the center of many human cancers (Dang,
2012; Eilers and Eisenman, 2008). The MYC (c-MYC) gene is
frequently amplified in human cancers (Ciriello et al., 2013),
and the highly relatedMYCN (N-MYC) is amplified in poor-prog-
nosis neuroblastoma (Maris, 2010). MYC heterodimerizes with
its partner MAX to bind E-box sequences or non-canonical sites
in target gene promoters or enhancers and regulate transcription
(Wolf et al., 2015). Aberrant expression of MYC results in upregu-
lation of many target genes, particularly those involved in glycol-
ysis, oxidative metabolism, glutamine metabolism, mitochon-
drial and ribosomal biogenesis, cell growth, and cell cycle
regulation (Eilers and Eisenman, 2008). Intriguingly, while MYC
has not been previously implicated in control or regulation of
circadian rhythm in cancer cells, E-box elements bound by
MYC drive expression of metabolic genes, such as nicotinamideolism 22, 1009–1019, December 1, 2015 ª2015 Elsevier Inc. 1009
phosphoribosyltransferase (NAMPT) (Menssen et al., 2012), that
are also bound by the central molecular clock heterodimeric
transcription factor CLOCK-BMAL1, which controls rhythmic
circadian gene expression (Dang, 2012; Hogenesch et al.,
1998; Ramsey et al., 2009). The molecular clock is driven by a
key feedback loop, in which CLOCK-BMAL1 induces PER and
CRY proteins, which in turn form inhibitory complexes with
CLOCK-BMAL1 (Sato et al., 2006). CLOCK-BMAL1 also induces
REV-ERBa and REV-ERBb (Bugge et al., 2012; Cho et al., 2012),
which transcriptionally repress BMAL1 at retinoic acid receptor-
related orphan receptor elements (ROREs), thereby constituting
a second important interlocking feedback loop (Preitner et al.,
2002).
Circadian rhythms are 24-hr cycles that control metabolic
gene expression and cell division as well as other physiological
processes, such as blood pressure and body temperature,
coupling food availability and sleep with cellular metabolism
(Bass and Takahashi, 2010). In mammals, the central clock is
located within the suprachiasmatic nucleus (SCN) of the brain
that senses light and synchronizes peripheral clocks through hu-
moral, neuronal, and behavioral cues (Bass and Takahashi,
2010). The peripheral clocks, which are present in nearly every
cell in the body (Bass and Takahashi, 2010), operate indepen-
dently from the central clock and can be entrained by feeding
in addition to temperature and synchronization cues from the
central clock.
Mutations of circadian genes occur in many cancers, but
their functional consequences are not well understood (Savvidis
and Koutsilieris, 2012). Two key circadian genes, PER1 and
PER2, have been identified as putative tumor suppressors in
salivary gland, gastro-intestinal system, breast tissue, and the
immune compartment (Savvidis and Koutsilieris, 2012; Zhao
et al., 2014). Loss of PER2 function predisposed genetically en-
gineered mice to spontaneous lymphomagenesis, but mouse
strain specificity was not documented (Fu et al., 2002). Hemato-
logic malignancies such as diffuse large B cell lymphoma,
chronic lymphocytic leukemia, and acute myeloid leukemia
show strong downregulation of the central circadian regulator
BMAL1 (Taniguchi et al., 2009). Indeed, recent studies identify
BMAL1 as a putative tumor suppressor (Savvidis and Koutsilie-
ris, 2012; Yeh et al., 2014). Ovarian cancers have altered circa-
dian gene expression and oscillation compared to normal tissue,
but the functional significance and mechanism for these alter-
ations were not established (Tokunaga et al., 2008). Still other
studies found circadian gene expression alterations in cancers
such as pancreatic, prostate, and glioma (Savvidis and Koutsilie-
ris, 2012). Importantly, altered circadian rhythm may affect can-
cer treatment outcomes, as studies in mice and humans have
identified circadian-dependent toxicity in more than 40 anti-
cancer agents, including antimetabolites, mitosis inhibitors,
alkylating agents, and cytokines (Le´vi et al., 2010). Thus, altered
circadian gene expression occurs broadly in cancer; however, it
is not known whether MYC could contribute to disruption of
circadian gene expression.
Given that the target core consensus sequence of CLOCK-
BMAL1 appears identical to those recognized by MYC, we
have previously hypothesized that oncogenic MYC could disrupt
the molecular clock in vitro through dysregulating E-box-driven
components of the clock machinery and thereby perturb circa-1010 Cell Metabolism 22, 1009–1019, December 1, 2015 ª2015 Elsedian influence of central bioenergetic metabolism (Dang, 2012).
Here, we report that MYC directly activates expression of multi-
ple repressors of the clock and disrupts the circadian oscillation
of the BMAL1::luciferase reporter and BMAL1 (ARNTL) mRNA.
Through loss-of-function studies, we found that REV-ERB induc-
tion by MYC functionally contributes to the repression and
dampening of BMAL1 oscillation. Further, N-MYC also induces
REV-ERBa (NR1D1), whose elevated expression suppresses
BMAL1 and portends poor clinical outcome for neuroblastoma
patients. We also found that ectopic expression of BMAL1 re-
duces the clonogenicity of neuroblastoma cell lines, supporting
the putative tumor suppressive function of BMAL1 (Yeh et al.,
2014). Importantly, we found that MYC not only disrupts the
circadian clock, but it also profoundly perturbs circadian glucose
metabolism and glutaminolysis, favoring MYC-induced biosyn-
thesis for cell growth. Our findings indicate that MYC and N-
MYC, which are frequently deregulated in human cancers, can
disrupt the cellular molecular clock and significantly affect
cellular metabolism.
RESULTS
MYC Disrupts Circadian Oscillation of BMAL1 Levels in
Cultured Cells
We sought to determine whether ectopic MYC expression could
disrupt the cellular clock machinery. We used the human osteo-
sarcoma cell line U2OS, which is a commonly used line to study
circadian rhythm and has been engineered to stably express
luciferase under the control of the BMAL1 promoter such that
circadian oscillation of luciferase can be observed with the Lumi-
Cycle luminometer in real time after synchronizing the cells with
dexamethasone (Baggs et al., 2009; Balsalobre et al., 2000). As
U2OS cells have relatively low endogenous MYC (Walz et al.,
2014), we stably expressed inducible wild-type MYC-ERTM
(estrogen receptor tamoxifen mutant) or a mutant MYC-ERTM
D106-143, which lacks the transactivation MYC Box II domain
(Littlewood et al., 1995) (Figure 1A inset). When stimulated with
4-hydroxytamoxifen (4OHT, MYC-ON), MYC-ER translocated
into nucleus and upregulated the MYC targets ornithine decar-
boxylase 1 (ODC1) and NAMPT, demonstrating the increased
activity of MYC (Figure 1B) (Menssen et al., 2012; Walz et al.,
2014). In contrast, cells expressing mutant MYC-ER D106-143
showed only slight upregulation of ODC1 and no upregulation
of NAMPT in response to 4OHT stimulation (Figure 1C). While
vehicle-treated (EtOH-treated, MYC-OFF) dexamethasone-syn-
chronized U2OSMYC-ER cells showed 24-hr oscillation of lucif-
erase, activation of MYC-ER with 4OHT profoundly ablated this
oscillation (Figures 1A and S1A). By contrast, this oscillation was
not diminished in MYC-ER D106-143-expressing cells treated
with 4OHT (Figures 1A and S1A) or in cells that were uninfected
or transduced with control empty vector (Figures 1D and S1B).
Collectively, these observations documented that wild-type
MYC activity dampens the oscillating circadian activity of the
BMAL1 promoter.
Next, we collected RNA every 4 hr and assessed endogenous
circadian gene expression by qPCR in synchronized U2OS
cells. Endogenous BMAL1 (ARNTL) mRNA level was strongly
decreased and oscillation significantly blunted by MYC activa-
tion (Figure 1E). The endogenous core circadian factor PER2vier Inc.
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Figure 1. MYC Disrupts Circadian Rhythm
(A) U2OS BMAL1::Luc cells stably expressing either
human wild-type MYC-ERTM or human MYC-ERTM
D106-143 (as visualized by immunoblot, inset) were
treated with 4-hydroxytamoxifen (4OHT, MYC-ON)
to activate MYC-ERTM or ethanol (EtOH, MYC-OFF)
control and synchronized with dexamethasone.
BMAL1 promoter activity luminescence was con-
tinuously measured (every 10 min) in a LumiCycle
luminometer. Data are representative of more than
three experiments.
(B and C) Expression of ornithine decarboxylase
(ODC1) or NAMPT in U2OSMYC-ERTM (B) orMYC-
ERTM D106-143 cells (C) as determined by RT-
PCR, normalized to beta-2-microglobulin (b2M).
Data are shown as means ± SD (n = 4). mRNA
(FC) = Fold Change, ns = not significant.
(D) U2OSBMAL1::Luc cells expressing pBabe-Zeo
empty vector (ev) or mock infected were cultured
with 4OHT or ethanol, synchronized with dexa-
methasone, and monitored in LumiCycle lumin-
ometer. Data are representative of three or more
experiments.
(E and F) Endogenous BMAL1 (E) or PER2 mRNA
expression (F) in synchronized U2OS MYC-ER
cells was determined by RT-PCR, normalized to
b2M. Data are representative of two or more ex-
periments.
(G) Immunoblot of tetracycline regulated MYC in
mHCC 3-4 cells. Tubulin serves as loading control.
(H) Expression of ODC1 and NAMPT in mHCC 3-4
cells as determined by RT-PCR. Data are shown as
means ± SD (n = 5).
(I) mHCC 3-4 BMAL1::Luc cell clone (c12) treated
with tetracycline (tet, MYC-OFF) or control (tet,
MYC-ON) and synchronized with dexamethasone
was monitored as in (A). RLU = relative light units.
For (B), (C), and (H), *p < 0.05 by Student’s t test of
MYC-ON samples relative MYC-OFF samples.mRNA level was increased, but oscillation was also altered by
MYC (Figure 1F). The fact that PER2 continued to oscillate
with a disrupted phase is consistent with previously published
results showing that static BMAL1 mRNA expression alters
but does not eliminate PER oscillation (McDearmon et al.,
2006). These data indicated that MYC affects not only the
BMAL1 promoter-reporter, but also endogenous cycling of
circadian genes.
To determine whether MYC-mediated disruption of circadian
oscillation of BMAL1 promoter function could be restored in
cancer, we used the mouse hepatocellular carcinoma cell line
mHCC 3-4 derived from a liver tumor with a conditional c-MYC
Tet-Off expression system (Shachaf et al., 2004; Xiang et al.,
2015) (Figure 1G). Ectopic MYC predictably increased levels of
Odc1 and Nampt mRNAs (Figure 1H). As previously done in
U2OS cells (Baggs et al., 2009), we produced MYC-transformed
mHCC 3-4 cells that stably express BMAL1::Luc. By LumiCycleCell Metabolism 22, 1009–1019, Dluminometer analysis, circadian oscilla-
tion was restored with diminished ectopic
MYC expression in this mouse liver can-
cer-derived cell line in multiple clones
(Figures 1I, S1C, and S1D). Reduction ofectopic MYC expression also appeared to restore the expres-
sion of BMAL1 (Arntl) mRNA at later time points (Figure S1E)
and reduced Per2mRNA levels (Figure S1F). These observations
collectively indicated that MYC overexpression alters circadian
oscillation in different cell types and that diminished MYC
expression in a MYC-driven tumor-derived liver cancer cell line
could partially restore BMAL1 promoter activity oscillation.
MYC Upregulates Circadian Repressor Genes and
Downregulates BMAL1 Expression
To delineate the mechanism by which MYC disrupts BMAL1
oscillation, we hypothesized that MYC transactivates E-box-
driven BMAL1 repressors, such as PER and CRY, REV-ERBa
(NR1D1), or REV-ERBb (NR1D2) (Bass, 2012; Bass and Takaha-
shi, 2010). We observed that MYC significantly upregulated
levels of PER2, CRY1, REV-ERBa, and REV-ERBb mRNAs in
both U2OSMYC-ER (Figure 2A) andmHCC 3-4 (Figure 2B) cells.ecember 1, 2015 ª2015 Elsevier Inc. 1011
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Figure 2. MYC Upregulates Circadian
Repressor Genes
(A) Expression of clock factor genes (indicated
above each graph) in (A) U2OS MYC-ER cells
treated with either 4OHT (MYC-ON) or EtOH
(MYC-OFF) control for 24 hr.
(B) mHCC 3-4 cells treated with (+Tet, MYC-OFF)
or without (Tet, MYC-ON) tetracycline for 24 hr,
or (C) U2OS MYC-ERTM D106-143 cells treated
with either 4OHT (MYC-ON) or EtOH (MYC-OFF)
control for 24 hr. mRNA expression determined by
RT-PCR was normalized to b2M expression.
mRNA (FC) = Fold Change.Means and SDs from at
least three experiments are shown. *p < 0.05 by
Student’s t test of 4OHT (MYC-ON) samples rela-
tive to EtOH (MYC-OFF) samples or Tet (MYC-
ON) samples relative to +Tet (MYC-OFF) samples,
ns = not significant.Some variation was observed between cell lines, as Per1 was
upregulated by MYC in mHCC 3-4 but not in U2OS MYC-ER.
In contrast to wild-type MYC, the inactive MYC-ER D106-143
mutant did not show significant upregulation of any circadian
genes upon treatment with 4OHT, and slight downregulation
of steady-state BMAL1 expression in U2OS cells (Figure 2C).
To determine whether PER, CRY, REV-ERBa, and REV-ERBb
behave as direct MYC target genes, we analyzed publicly avail-
able MYC chromatin immunoprecipitation (ChIP) data from
multiple cancer cell lines and U2OS cells with inducible MYC,
and we also performed promoter studies with U2OS and
mHCC (see Supplemental Experimental Procedures and Figures
S2 and S3A–S3C). We found that each of these genes, with the
exception of BMAL1 (ARNTL), could be induced and bound by
MYC and hence behave as direct MYC targets in multiple cell
lines. These observations suggested that MYC could induce
the expression of negative regulators of BMAL1, which can in
turn disrupt the molecular clock in vitro.1012 Cell Metabolism 22, 1009–1019, December 1, 2015 ª2015 Elsevier Inc.REV-ERBa and b Are Necessary
for Disruption of Circadian Rhythm
by MYC
To delineate which BMAL1 repressors
were responsible for disruption of circa-
dian rhythm, we used siRNAs against
the repressors to determine whether
diminished expression could rescue
MYC-mediated disruption of BMAL1-
promoter circadian rhythm. PER and
CRY negatively regulate circadian rhythm
by repressing CLOCK-BMAL1 activity
(Bass, 2012; Bass and Takahashi, 2010).
We used siRNAs targeting CRY1 and
PER2, which were consistently induced
by MYC in multiple cell lines (Figure 2),
in U2OS cells expressing MYC-ER to
determine if they were responsible for
the downregulation of BMAL1 and disrup-
tion of circadian oscillation byMYC.While
we observed a significant reduction in
the expression of each gene after siRNAtreatment (Figure 3A), neither PER2 norCRY1 knockdown signif-
icantly rescued either BMAL1 mRNA expression suppressed
by MYC (Figure 3B) or the blunted BMAL1::Luc oscillation in
MYC-ER-activated U2OS cells (Figure 3C). These data suggest
that while PER2 and CRY1 behave as MYC targets, they may
not be functionally responsible for disruption of BMAL1::Luc
oscillation by MYC in U2OS cells. However, MYC’s induction
of PER2 and CRY1 may still alter the molecular clock, because
of their effects on BMAL1 protein activity rather than BMAL1
mRNA. Further, their reduction by siRNA to non-basal level could
confound the interpretation of their roles in the suppression of
BMAL1::Luc by MYC.
REV-ERBa is a transcriptional repressor that blunts BMAL1
expression and oscillation in U2OS cells (Preitner et al., 2002;
Relo´gio et al., 2011). Further, overexpression of REV-ERBa
in transgenic mouse liver suppressed BMAL1 levels and oscilla-
tion in vivo (Kornmann et al., 2007). REV-ERBa closely cooper-
ates with REV-ERBb to regulate gene expression and occupy
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Figure 3. REV-ERBa and b Are Necessary
for MYC Disruption of BMAL1 Promoter Oscil-
lation
(A) mRNA levels (normalized to expression of b2M)
for PER2 or CRY1 determined by RT-PCR in U2OS
MYC-ER cells transfected with either non-targeting
siRNA (Con), siRNA against PER2, or CRY1 for 48 hr
with 4OHT (MYC-ON) being added to cells 24 hr after
transfection. Means and SDs from at least three ex-
periments are shown. *p < 0.05 for Con versus siPER2
or siCRY1. mRNA (FC) = Fold Change.
(B) BMAL1 mRNA expression (normalized to ex-
pression of b2M) in U2OS MYC-ER transfected as
described in (A) with siRNAs indicated at the bottom.
*p < 0.05 by Student’s t test for MYC-ON versus
MYC-OFF. ns = not significant.
(C) U2OS MYC-ER cells were transfected with
siRNAs as indicated in the figure, synchronized with
dexamethasone and monitored using a LumiCycle
luminometer. Data are representative of two or more
experiments.
(D) mRNA levels (normalized to expression of b2M)
for REV-ERBa or REV-ERBb determined byRT-PCR in
U2OS MYC-ER cells transfected with either non-tar-
geting siRNA (Con), siRNA against REV-ERBa, REV-
ERBb, or both REV-ERBs (a+b) for 48 hr with 4OHT
(MYC-ON) beingadded to cells 24 hr after transfection.
Means and SDs from at least three experiments are
shown. *p < 0.05 for siREV versus control.
(E) BMAL1 mRNA levels (normalized to expression of
b2M) in U2OS MYC-ER transfected with the indi-
cated siRNAs (bottom) as described in (D) and
cultured with 4OHT (MYC-ON) or EtOH (MYC-OFF)
after 24 hr. Means and SDs from at least three ex-
periments are shown. *p < 0.05 by Student’s t test for
siREV or Con MYC-ON versus Con MYC-OFF. x, p <
0.05 siREV versus Con MYC-ON.
(F) U2OS MYC-ER cells transfected with the indi-
cated siRNAs for 48 hr, cultured with 4OHT (MYC-
ON) or EtOH (MYC-OFF), synchronized with dexa-
methasone, and monitored as in (C).
Data are representative of two or more experiments.
RLU = relative light units.promoter elements; hence, elimination of both a and b pro-
foundly disrupted circadian rhythm while elimination of REV-
ERBa alone only had mild effects on circadian oscillation (Bugge
et al., 2012; Cho et al., 2012). Thus, to determine whether
MYC disrupted circadian rhythm through REV-ERB genes,
we targeted REV-ERBa, REV-ERBb, or both genes with
siRNAs in U2OS MYC-ER (Figure 3D). While siRNA knockdownCell Metabolism 22, 1009–1019of either REV-ERBa or REV-ERBb increased
BMAL1 expression in MYC-activated cells,
knockdown of both genes together led to a
complete rescue of BMAL1 expression in
the presence of MYC (Figure 3E). Note that
REV-ERB knockdown in MYC-OFF cells
also increased basal BMAL1 mRNA levels
as expected (Figure 3E). Knockdown of
REV-ERBa in mHCC 3-4 cells also led to a
significant rescue in BMAL1 mRNA expres-
sion (Figure S3D). Importantly, knocking
down both REV-ERB mRNAs substantiallyrescued the MYC-ER-mediated dampened expression and
oscillation of BMAL1::Luc in U2OS cells, while individual REV-
ERB gene knockdown could partially rescue the dampening ef-
fects of MYC (Figure 3F). These data suggested that MYC’s
disruption of circadian rhythm is largely carried out through
MYC-mediated upregulation of REV-ERB transcription. In fact,
we also observed that high MYC expression in a panel of, December 1, 2015 ª2015 Elsevier Inc. 1013
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Figure 4. N-MYC Directly Upregulates REV-
ERBa and Disrupts Circadian Rhythm
(A) REV-ERBa and BMAL1 mRNA expression
(normalized to expression of b2M) determined by
RT-PCR in Shep N-MYC-ER expressing neuro-
blastoma cells with MYC-ON or MYC-OFF. mRNA
(FC) = Fold Change. Means and SDs from at least
three experiments are shown. *p < 0.05 by Stu-
dent’s t test for MYC-ON versus MYC-OFF.
(B) Chromatin immunopreciptitation (ChIP) anal-
ysis with anti-N-MYC antibody in MYC-ON versus
MYC-OFF in Shep N-MYC-ER cells. ChIP signals
(% input) are shown for the Rev-erba promoter E-
box region (REVa, 81 bp region), 2 kb upstream of
REV-ERBa transcription start site (REVa-2k), and
the promoter of the canonical MYC target nucle-
ophosmin 1 (NPM1). Means and SDs from tech-
nical triplicates are shown. *p < 0.05 by Student’s
t test for MYC-ON versus MYC-OFF. Data are
representative of three or more experiments.
(C) Activity of the REV-ERBa promoter::luciferase
construct (1156 to +31 region) in Shep N-MYC-
ER-expressing cells expressing under MYC-ON
versus MYC-OFF conditions. RLU: relative light
unit. Means and SDs from triplicate samples are
shown, and *p < 0.05 by Student’s t test for MYC-
ON versus MYC-OFF. Data are representative of
three or more experiments.
(D) Time series (every 4 hr) expression of BMAL1
(left panel) or PER2 (right panel) mRNA (relative to
b2M) determined by RT-PCR in synchronized
Shep N-MYC-ER-expressing cells with MYC-ON
or MYC-OFF. Data are representative of two or
more experiments.
(E) Kaplan-Meier survival analysis of patients with
neuroblastoma expressing different levels of
MYCN or (REV-ERBa)NR1D1 analysis grouped by
tertiles based on individual gene expression. Log
rank p values are shown.
(F) Ectopic expression of BMAL1 (ARNTL, specific
band indicated by <) in the high MYCN neuro-
blastoma cell lines NLF and Kelly was determined
by immunoblotting, with Tubulin serving as a
loading control.
(G) Colony suppression assay of cells treated
with 1 mg/ml G418 showed that ectopic expres-
sion of ARNTL suppressed colony formation capacities of NLF and Kelly cells as compared with vector control (ev).
(H) Quantitation of colony suppression by ARNTL determined by area of colonies on culture plates measured by ImageJ. n = 3, error bars represent SD. *p < 0.05
by Student’s t test.human-derived T-ALL (T cell acute lymphoblastic leukemia) lines
correlates with increased REV-ERBa expression (Figures S3E
and S3F).
N-MYC Disrupts Circadian Gene Expression and
Oscillation
It has been shown previously that c-MYC and N-MYC, encoded
by the MYCN gene, have overlapping functions, targets, and
binding motifs (Malynn et al., 2000). Given the functional similar-
ities betweenMYC andN-MYC, we sought to determine whether
N-MYC could also induce REV-ERBa expression like MYC. To
study N-MYC, we used the human neuroblastoma cell lines
Shep N-MYC-ER and SKNAS N-MYC-ER (Ushmorov et al.,
2008; Valentijn et al., 2005). Both Shep and SKNAS lack ampli-
fied N-MYC, but when ectopic N-MYC-ER was activated with1014 Cell Metabolism 22, 1009–1019, December 1, 2015 ª2015 Else4OHT (MYC-ON), the canonical Myc targets ODC1 and NAMPT
were induced (Figures S4A and S4B). N-MYC activation also re-
sulted in strong upregulation of REV-ERBa and downregulation
of BMAL1 (Figures 4A and S4B). PER1, PER2, and CRY1 were
similarly upregulated in the presence of 4OHT, suggesting that
N-MYC perturbs circadian gene regulation like MYC (Figures
S4A and S4B). These data suggest that inducible N-MYC simi-
larly disrupts circadian gene expression in two different neuro-
blastoma cell lines.
Corroborating the findings with the N-MYC-ER models, REV-
ERBa expression also positively tracks with expression of
N-MYC in three different neuroblastoma cell lines (Shep, NLF,
and Kelly) with varying MYCN expression levels (Figure S4D).
Like MYC in U2OS cells, N-MYC directly bound the promoter re-
gions of REV-ERBa and NPM1 in Shep N-MYC-ER, but not withvier Inc.
a region of DNA 2,000 bases upstream from the REV-ERBa pro-
moter start site (Figure 4B). Shep N-MYC-ER cells expressing a
REV-ERBa::luciferase reporter also showed increased luciferase
activity in the presence of 4OHT (Figure 4C), indicating that REV-
ERBa is a direct target of N-MYC. Consistent with MYC upregu-
lating REV-ERBa, Shep and SKNAS N-MYC-ER cells with active
N-MYC-ER (MYC-ON) showed greatly diminished expression
and disrupted oscillation of BMAL1 (Figures 4D and S4C), as
well as increased amplitude and altered oscillation of PER2 (Fig-
ures 4D and S4C), consistent with results from U2OS andmHCC
3-4 cells. Importantly, this same trend was found in the three
neuroblastoma cell lines (Figure S4D); we observed some circa-
dian BMAL1 oscillation in the N-MYC single copy Shep cells, but
not in the N-MYC amplified NLF or Kelly lines (Figure S4E).
Increased REV-ERBa andDecreased BMAL1 Expression
Correlate with High Risk Neuroblastoma, and BMAL1
Functions as a Tumor Suppressor inMYCN Amplified
Neuroblastoma Cells
We analyzed gene expression from a collection of human pri-
mary neuroblastoma tumor samples to establish the potential
clinical relevance of N-MYC regulation of REV-ERBa in human
neuroblastoma (Wang et al., 2006). Consistent with previous
findings, patients with the highest MYCN-expressing neuro-
blastomas had the worst survival outcomes (Figure 4E). Intrigu-
ingly, elevated REV-ERBa alone also highly correlated with
poor prognosis (Figure 4E), suggesting that REV-ERBa may
play a role in the aggressiveness of neuroblastoma. REV-ERBa
(NR1D1) expression was elevated in high-risk tumors, par-
ticularly those with MYCN amplification, compared to tumors
classified as low or intermediate risk (Figure S5A) (Pugh et al.,
2013). Conversely, BMAL1 (ARNTL) expression was lowest in
the high-risk MYCN-amplified group (Figure S5B). Further, low
BMAL1 or high REV-ERBa expression also correlated with
poor prognosis in two different patient cohorts (Figures S5C–
S5E) (Kocak et al., 2013). Together, these data suggested that
overexpressed N-MYC, as observed in cell lines and in primary
patient samples, specifically upregulates REV-ERBa, which de-
creases BMAL1 expression and disrupts the molecular clock in
neuroblastoma.
The decreased BMAL1 expression in high-risk neuroblastoma
could be related to its putative tumor suppressor function (Yeh
et al., 2014). To determine its tumor suppressive role, we over-
expressed BMAL1 in NLF and Kelly neuroblastoma cell lines
that have high N-MYC expression (Figure S4D) and assessed
BMAL1’s effect on colony formation. BMAL1 was expressed
by transient transfection of pCMV6-ARNTL (BMAL1), and the
pCMV6 empty vector (Ev) served as control (Figures 4F and
4G). Cells were then selected with G418 and stained with crystal
violet. As shown in Figure 4H, ectopic BMAL1 expression signif-
icantly suppressed colony formation in both NLF and Kelly cells,
illustrating a tumor suppressive function of BMAL1.
MYC Disrupts Circadian Oscillation of Glycolysis and
pAMPK and Alters Glutamine Metabolism
To determine whether MYC-mediated disruption of the circadian
transcription factor network altered metabolism, we performed
targeted metabolomics using NMR focusing on glucose, lactate,
glutamine, glutamate, and pyruvate levels in culture media andCell MetabU2OS MYC-ER cells. In a time-series experiment at 2 hr in-
tervals, media and cells from MYC-OFF (EtOH) or MYC-ON
(4OHT) conditions were harvested for measurements of metab-
olites over a period of 48 hr, 24 hr after dexamethasone synchro-
nization, without changing the media. NMR peak intensities
were quantified at each time point and were subjected to de-
trending and JTK (Jonckheere-Terpstra-Kendall) cycle analysis
to identify oscillation among the selected metabolites (see Fig-
ure S6 for example NMR spectra) (Hughes et al., 2010; Weljie
et al., 2006). As shown in Figure 5A, glucose was consumed at
a higher rate in MYC-ON cells than MYC-OFF cells, which dis-
played phases of glucose consumption with slowed rates of
loss from the media between 14 and 24 hr. Intriguingly, intracel-
lular glucose levels oscillated in a circadian manner (JTK cycle
time = 24 hr; p value = 0.052; ‘‘adjusted’’ intracellular levels
reflect concentrations in the extracts and not actual intracellular
concentrations), peaking at about 12 and 36 hr. By contrast,
while MYC-ON cells consumed glucose from the media at a
higher rate, intracellular glucose levels were so low that circadian
oscillation is not discernible, suggesting that glucose was
consumed for biosynthesis as postulated (Murphy et al., 2013).
Consistent with MYC-driven biosynthesis, MYC-ON U2OS
cells had remarkably low intracellular lactate levels relative to
MYC-OFF cells, while extracellular lactate levels in the media
accumulated to high levels for MYC-ON cells compared with
MYC-OFF cells (Figure 5A). It is notable that the apparent oscil-
lation of media lactate levels in MYC-OFF cells paralleled
changes in cellular glucose levels; however, the oscillation in
the media did not reach statistical significance by JTK analysis.
The significant disappearance of pyruvate from the medium of
MYC-ON cells as compared with MYC-OFF cells (Figure 5A)
supports the notion of MYC-driven biosynthesis, particularly
since intracellular pyruvate levels were below the detection
limit of this NMR approach. These patterns reveal a previously
unsuspected circadian oscillation of glucose metabolism and
its conversion to lactate in synchronized U2OS cells, which
were disrupted by induction of MYC, suggesting that MYC-
mediated disruption of the circadian clock perturbs metabolic
oscillation.
We also examined glutamine and glutamate and found that
U2OS cells readily consumed glutamine, and the consumption
was further heightened by the induction of MYC (Figure 5A).
Intracellular glutamine levels were below detection limit in both
MYC-ON andMYC-OFF cells (not shown). Notably, media gluta-
mate levels were generally higher forMYC-ON cells compared to
MYC-OFF cells. Intracellular glutamate decreased in MYC-ON
cells while it accumulated in MYC-OFF cells, seemingly in a
circadian fashion (which did not reach statistical significance
by JTK analysis), suggesting glutamine and derived glutamate
were consumed for biosynthesis in MYC-ON cells. These obser-
vations collectively illustrate that circadian fluctuation of key me-
tabolites involved in glycolysis and glutaminolysis in U2OS cells
was profoundly disrupted by MYC activation, which is known to
drive biosynthesis for cell growth (Murphy et al., 2013).
To gain further insight into the bioenergetics of U2OS cells with
different MYC activities, we analyzed phosphorylated AMPK
(pAMPK T172) as a surrogate measure of cellular energy status.
As shown in Figure 5B, pAMPK levels were higher, particularly at
later time points, and oscillating in MYC-OFF cells as comparedolism 22, 1009–1019, December 1, 2015 ª2015 Elsevier Inc. 1015
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Figure 5. MYC Suppresses Circadian Oscil-
lation of Glucose Metabolism and Alters
Glutamine Metabolism in U2OS Cells
(A) Cellular (Cells) or media metabolite (top labels)
levels determined by NMR spectroscopy are shown
for a time-series experiment with 2-hr intervals
from U2OS with MYC-OFF (EtOH) or MYC-ON
(4OHT), 24 hr after initial dexamethasone synchro-
nization. Concentrations for metabolites represent
the adjusted concentration for cells, based on
extraction volume, or the actual concentration of
media metabolites. For each metabolite profile, the
time-series data were plotted using the JTK v2
algorithm after linear detrending, and rhythmicity
was assessed via a non-parametric cosine function
fit. The colored bands represent 95% confidence
intervals from the locally weighted scatterplot
smoothing function that generated the curves. p
values indicate the significance of the cosine wave
fit to experimental data. Note that MYC-ON media
24-hr sample and MYC-ON cells 48-hr sample
were excluded due to inconsistencies in sample
measurements.
(B) Synchronized U2OS MYC-ER cells were har-
vested after treatment and lysates were processed
for immunoblots of hexokinase 1 (HK1), hexokinase
2 (HK2), phospho-AMP kinase (pAMPK Thr172),
AMP-kinase (AMPK), BMAL1, and PER2 (indicated
by < ). Tubulin serves as a loading control. Data are
representative of two individual experiments.with MYC-ON cells. Oscillation of pAMPK levels was in-phase
with intracellular glucose levels and appears to correlate with
high intracellular lactate levels (glycolysis). pAMPK levels were
at their lowest level when intracellular glucose levels were lowest
(Figure 5B) in MYC-OFF cells. Intriguingly, the levels and oscilla-
tion of pAMPK were suppressed in MYC-ON cells, suggesting
that the bioenergetics status of MYC-driven U2OS cells was
sustained by increased glutaminolysis and consumption of
glucose. We also determined levels of hexokinases, HK1 and
HK2, and found that both enzyme levels, particularly HK1,
appear to oscillate (minimally) in phase with glucose consump-
tion in MYC-OFF cells (Figure 5B). However, in MYC-ON cells,
HK2, a known MYC target (Kim et al., 2007), was induced and
ceased to oscillate. Note that these changes correspond to
MYC-induced decreased BMAL1 and increased PER2 protein
levels (Figure 5B). These observations demonstrate that, in addi-
tion tometabolic oscillation, the bioenergetic status ofMYC-OFF
U2OS cells also oscillated in a manner that is suppressed by1016 Cell Metabolism 22, 1009–1019, December 1, 2015 ª2015 Elsevier Inc.ectopic MYC activity, which drives glycol-
ysis and glutaminolysis for biosynthesis.
DISCUSSION
MYC and circadian rhythm are frequently
altered in cancer (Sahar and Sassone-
Corsi, 2009), but whether this altered
circadian rhythm can be mechanistically
linked to deregulated MYC transcriptional
function in cancer has not been deter-
mined. Our work here documents thepreviously unsuspected role of oncogenic MYC in the disruption
of the molecular clock and metabolic oscillation in vitro,
providing a foundation for future in vivo studies. We found
that oncogenic MYC disrupts circadian oscillation through upre-
gulation of REV-ERBa and REV-ERBb, which in turn dampen
BMAL1 expression and oscillation (Figure 6); however, we
have not excluded the possible roles of MYC-induced CRY
and PER in MYC-mediated clock disruption. Specifically, it is
notable that MYC increased PER2 mRNA and protein levels
while perturbing the circadian oscillation of PER2 expression
(Figures 1F and 5B). We demonstrate that MYC directly bound
to the promoter of REV-ERBa and upregulated its transcription,
leading to lower levels of BMAL1 expression and loss of rhyth-
micity. These data are consistent with previous studies showing
that ectopic REV-ERBa expression can dampen the oscillation
of BMAL1, both in vitro and in vivo (Kornmann et al., 2007; Relo´-
gio et al., 2011). Our finding that MYC could occupy circadian
E-boxes as previously proposed (Kondratov et al., 2006) is
AB
Figure 6. Model of Circadian Rhythm Disruption by MYC
(A and B) Summary diagram of normal molecular clock (A) andmolecular clock
disrupted by MYC (B).consistent with a study showing that the E-box binding helix-
loop-helix leucine zipper transcription factor USF1 can also
compete with CLOCK-BMAL1 to bind to circadian regulatory el-
ements (Shimomura et al., 2013). However, we have not distin-
guished between E-box co-occupancy or competition between
MYC and CLOCK-BMAL1.
During the course of our studies, a recent report documented
a role for MYC in disrupting the emergence of the circadian
clock during differentiation of embryonic stem cells (Umemura
et al., 2014). However, in these normal cells, MYC disruption of
the circadian clock was dominated by a block in PER nuclear
import rather than a direct effect on circadian E-boxes as we
demonstrated in cancer cell lines. Our observations underscore
the complexity of MYC-mediated transcription, which does not
simply amplify expression of genes that are already expressed.
Rather, MYC-mediated gene expression culminates from the
intricate interplay between MYC and other transcription factors
such asMIZ-1, which can result in time-dependent gene expres-
sion changes particularly when the molecular clock transcription
factors are involved (Wolf et al., 2015).
While REV-ERBa was universally upregulated by MYC and
N-MYC in all cell lines and databases we queried, REV-ERBb up-
regulation was less consistent across these cell lines, despite
also being predicted as a MYC target. Nonetheless, knockdown
of both REV-ERBb and REV-ERBa was required to substantially
rescue BMAL1::luciferase amplitude and oscillation, which were
inhibited by MYC. These observations are consistent with previ-
ous findings that REV-ERBa andREV-ERBb cooperate closely toCell Metabregulate transcription (Bugge et al., 2012; Cho et al., 2012), and,
as such, both would have to be considered together when study-
ing circadian gene oscillation.
Our observation that REV-ERBa expression induced by N-
MYC correlates with poor prognosis for neuroblastoma contrib-
utes to the notion that REV-ERBa expression might be important
in tumorigenesis. Notably, the REV-ERBa gene is co-amplified
with ERBB2 in some breast cancers and may play an important
role in the growth of the breast cancer cells (Kourtidis et al.,
2010). REV-ERBa has not been previously recognized as an
oncogene, but its suppression of BMAL1 could contribute to
its tumorigenic potential. In particular, BMAL1 has been impli-
cated as a tumor suppressor (Yeh et al., 2014), and our studies
corroborate this notion and illustrate that low BMAL1 expression
correlates with high-risk neuroblastoma and that ectopic expres-
sion of BMAL1 suppressed colony formation by two different
high N-MYC neuroblastoma cell lines.
Given that circadian rhythm controlsmetabolic function, circa-
dian oscillation therefore constrains metabolism at certain times
of the day (Bass, 2012). Hence, perturbation of circadian gene
expression, as is broadly found in cancer, could release the
circadian restraints on cancer metabolism. MYC can elevate
metabolic gene expression in transformed cells compared to
normal cells (Dang, 2012), whose expression of metabolic genes
is constrained by the molecular clock. We speculate that MYC
induction of REV-ERBa, which in turn suppresses BMAL1, could
lead to elevated, unconstrained expression of metabolic genes
through clock disruption to provide an advantage to cancer cells.
In this regard, we found for the first time that intracellular glucose
metabolism in synchronized U2OS cells oscillated in a circadian
fashion that was profoundly disrupted by MYC activation, which
induced high levels of HK2 and increase glucose flux and lactate
production. Our observations are consistent with a recent study
showing circadian oscillation of NADH/NAD+ ratio in epidermal
stem cells (Stringari et al., 2015). Significant changes in pAMPK,
lactate, pyruvate, glutamine, and glutamate in our studies are
consistent with a role of activated MYC in driving biosynthesis,
which correlates MYC’s ability to disrupt the circadian molecular
clock. However, our current study does not define the interplay
between MYC’s transcriptional disruption of the circadian clock
machinery and its direct regulation of metabolic genes. Further
studies will be required to parse the roles of MYC in genetic
and metabolic regulation of circadian rhythm.
Because MYC and MYCN are amplified or their expressions
are altered in at least 50% of cancers (Dang, 2012), our work
suggests that a large group of cancersmay have disrupted circa-
dian molecular clocks and metabolism. While the potential
tumorigenic advantage of an oncogene-disrupted circadian
rhythm needs to be further established in the future through
in vivo studies, we speculate that the differences between
normal cellular circadian gene expression and the arrhythmic
expression of circadian genes in cancer cells could potentially
be exploited to optimize cancer therapy.EXPERIMENTAL PROCEDURES
Detailed Experimental Procedures, including standard molecular techniques
such as PCR, immunoblotting, cell culture, transfection, and genomics studies
are described in the Supplemental Information.olism 22, 1009–1019, December 1, 2015 ª2015 Elsevier Inc. 1017
Real-Time Luminescence Monitoring
Lumicycle analysis of U2OS BMAL1::Luc cells was described previously
(Baggs et al., 2009). Cell culture plates were cultured with beetle luciferin
(Promega), sealed with high vacuum grease (Dow Corning), and measured
for luminescence after dexamethasone synchronization every 10 min for at
least 4 days on a Lumicycle luminometer, then presented as relative light units
(RLU) per second (Actimetrics). The experiments were performed with tech-
nical triplicates and multiple biological replicates.
Time-Series mRNA Experiments
MYC was activated one day prior to collection. Experiment was performed as
a ‘‘split time course.’’ Twenty-four hours prior to the start of the experiment,
half the cells were synchronized in dexamethasone, and at the start, the other
half of the cells were synchronized. At each time point, two plates were har-
vested representing 0 and 24 hr +dex, 4 and 28, etc., to arrive at a 52 hr
time course.
Generation of Cell Lines and Clonogenic Assay
Cells were transfected and selected as described in the Supplemental Infor-
mation. For neuroblastoma clonogenic suppression,ARNTL or control expres-
sion vectors were transfected and cells were selected with G418 before
staining with crystal violet. Plates were scanned and quantified with ImageJ,
and representative images were uniformly contrasted.
siRNA
Human or mouse SMARTpool siRNAs were purchased from Dharmacon (GE
Healthcare). Cells were transfected with siRNAs using Lipofectamine 2000
or RNAiMAX (Life Technologies). Non-targeting siRNAs with same molar
amount were used as negative control. For all experiments, a total of 60 nM
siRNA was used. For experiments in which REV-ERBa and REV-ERBb were
used together in Figure 3, 30 nM of each siRNA was used.
Primary Neuroblastoma Survival Data
For data in Figure 4, previously published data (Wang et al., 2006) for 92 human
tumorswere assessed for overall survival basedonMYCN,NR1D1, andARNTL
expression (Figure S5C). Survival analyses were performed using the methods
of Kaplan and Meier. Patients were divided into separate groups based on ter-
tiles of individual mRNA expression. For overall survival (OS), time was defined
as the time fromdiagnosis until the timeof death fromdisease or until the timeof
last contact if death did not occur. Patientswhowere alivewere censored at the
time last known alive. Log rank p values < 0.05were considered significant. Da-
tabases usedwereGEO:GSE3960, GSE45547 (Wang et al., 2006; Kocak et al.,
2013) and dbGap: phs000467 (Pugh et al., 2013).
Cell and Media Extraction for NMR Analysis
Snap-frozen U2OS cell pellets were thawed and extracted. The aqueous frac-
tion of an organic:aqueous extraction was dried and immediately prepared for
NMR analysis as described in the Supplemental Information using an Avance
III HD 700 MHz NMR spectrometer from Bruker Biospin.
Quantitative Analysis of Metabolite Oscillations
Output concentrations from the NMR analysis were imported into the R statis-
tical framework (http://www.R-project.org) and were noted to have significant
temporal change in overall concentrations. Oscillations were assessed using
the non-parametric JTK_CYCLE algorithm (Hughes et al., 2010), testing for
period lengths between 22 and 26 hr corresponding to circadian events. The
default cosine functionwas used to assess rhythmic patterns and significance.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2015.09.003.
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